Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of NSCLC * Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include: * Definitive treatment of stage III disease (most common) * Definitive treatment for locoregional recurrence of early stage disease * Definitive treatment of unresectable stage II disease * Preoperative treatment of stage III disease * Postoperative treatment after incomplete resection (uncommon) * Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy) * ECOG Performance Status 0-3 within 30 days prior to registration * Age ≥ 18 * Ambulates independently or with a cane (use of a walker not permitted) * Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial. Patients must agree to wear the device provided by the study. * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry. Exclusion Criteria: * Patients with a history of another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy for NSCLC * Patients receiving concurrent treatment for another c…